{"gene":"CCL5","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":2016,"finding":"Crystal and solution structures of CCL5 reveal that oligomerization is a polymerization process forming rod-shaped, double-helical oligomers. The CCL5 oligomer uses a positively charged KKWVR motif for glycosaminoglycan (GAG) binding, which is distinct from the partially buried BBXB motif used by monomers/dimers. Oligomerization and GAG binding are structurally separable features of CCL5 function.","method":"X-ray crystallography, biophysical analyses, mutational analysis of GAG-binding and oligomerization mutants","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures of CCL5 and GAG-bound oligomers with mutational validation in a single rigorous study","pmids":["27091995"],"is_preprint":false},{"year":2015,"finding":"NMR structural analysis of CCL5 dimers bound to chondroitin sulfate oligosaccharides shows that, in addition to the BBXB motif in the 40s loop, GAGs also contact residues in the N loop. GAG binding orientation is highly dependent on the sulfation pattern of N-acetylgalactosamine groups.","method":"Solution NMR, paramagnetic relaxation enhancement, intermolecular NOE constraints, structural modeling","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR with multiple orthogonal constraints (PRE, NOE) in a single rigorous structural study","pmids":["25982530"],"is_preprint":false},{"year":2015,"finding":"CCL5 binds to the surface of human endothelial cells in a regular filamentous pattern dependent on heparan sulfate. CCL5 mutants restricted in heparin binding, dimerization, or tetramerization failed to form filaments, suggesting that higher-order oligomers and GAG binding are required for physiologically relevant surface presentation and leukocyte recruitment.","method":"Immunofluorescence, electron microscopy, flow chamber assay, heparan sulfate-deficient cell lines, CCL5 oligomerization/GAG-binding mutants","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (EM, IF, functional flow assay) with structure-function mutants in a single study","pmids":["25791723"],"is_preprint":false},{"year":2001,"finding":"RANTES/CCL5 secreted by thrombin-stimulated platelets is immobilized on inflamed or atherosclerotic endothelial surfaces and triggers shear-resistant monocyte arrest under flow conditions. This deposition requires endothelial activation (e.g., by IL-1β) and is blocked by the RANTES receptor antagonist Met-RANTES or anti-RANTES antibody.","method":"ELISA, immunofluorescence, parallel-wall flow chamber with video microscopy, Met-RANTES/antibody inhibition, immunohistochemistry in ApoE-/- mice, ex vivo carotid artery perfusion","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, replicated across human and murine systems","pmids":["11282909"],"is_preprint":false},{"year":2003,"finding":"RANTES/CCL5 activates a G protein-coupled receptor (GPCR)-independent signaling pathway through interaction with glycosaminoglycan (GAG) chains of CD44. This RANTES–CD44 association forms a signaling complex containing CD44, Src kinases, and adapter molecules, activating the p44/42 MAPK pathway. CD44 knockdown via RNA interference abolished p44/42 MAPK activation by RANTES and reduced HIV-1 infectivity enhancement.","method":"Co-immunoprecipitation, RNA interference (CD44 knockdown), p44/42 MAPK phosphorylation assays, HeLa-CD4 cell HIV infectivity assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, RNAi knockdown, and functional HIV assay; multiple orthogonal methods in one study","pmids":["12714503"],"is_preprint":false},{"year":1999,"finding":"CCR5-mediated signaling by RANTES induces early responses (Ca2+ influx, receptor dimerization, tyrosine phosphorylation, Gαi and JAK/STAT association). In contrast to native RANTES, the derivative (AOP)-RANTES fails to trigger late responses including FAK association with the receptor complex, cell polarization, and chemotaxis, demonstrating that late signaling events are separable from early ones and are required for migration.","method":"CCR5-transfected HEK-293 cells, Ca2+ flux assays, receptor dimerization assays, tyrosine phosphorylation assays, FAK co-immunoprecipitation, chemotaxis assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays with pharmacological dissection of early vs. late signaling in a single study","pmids":["10037796"],"is_preprint":false},{"year":2006,"finding":"CCL5-induced apoptosis in CCR5-expressing T cells requires (1) CCR5 expression, (2) tyrosine 339 of CCR5, (3) cell surface GAG binding (heparin/chondroitin sulfate addition or GAG digestion protects from death), and (4) higher-order CCL5 oligomerization—the non-GAG-binding mutant (44AANA47)-CCL5 and the dimer-restricted E66S mutant fail to induce apoptosis, while tetramer-forming E26A does. Apoptosis involves cytochrome c release, caspase-9 and caspase-3 activation, and PARP cleavage.","method":"CCR5-expressing and CCR5-null T cell lines, CCR5 tyrosine mutant (Y339F), GAG-binding CCL5 mutants, oligomerization CCL5 mutants, caspase activity assays, cytochrome c release assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution with structure-function mutants (receptor and ligand), multiple mechanistic readouts in one study","pmids":["16807236"],"is_preprint":false},{"year":2012,"finding":"CCL5 promotes migration of human osteosarcoma cells through CCR5 (not CCR1 or CCR3) by activating MEK→ERK→NF-κB signaling, which upregulates αvβ3 integrin expression. CCR5 siRNA/antibody/inhibitor and CCL5 shRNA each reduce migration and integrin upregulation.","method":"siRNA knockdown, CCR5 antibody, pharmacological inhibitors (MEK, ERK, NF-κB), integrin expression assays, migration assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors with siRNA validation in a single study, single lab","pmids":["22506069"],"is_preprint":false},{"year":2009,"finding":"CCL5-induced migration and invasion of human hepatoma cells through CCR1 requires syndecan-1 (SDC-1) and syndecan-4 (SDC-4) as co-receptors. Antibody blockade or siRNA knockdown of SDC-1 or SDC-4 reduces CCL5-induced chemotaxis and spreading. A GAG-binding-deficient CCL5 mutant (R47K) has no effect, confirming the necessity of chemokine–proteoglycan interaction. Oligomerization interference also reduces CCL5-mediated chemotaxis.","method":"Pharmacological inhibitors (FAK, PI3K, MAPK, ROCK), RNA interference (SDC-1, SDC-4), CCL5 oligomerization and GAG-binding mutants, Boyden chamber migration/invasion assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi + mutant CCL5 + pharmacological inhibitors with migration assay, single lab","pmids":["19632304"],"is_preprint":false},{"year":2009,"finding":"CCL5 promotes oral cancer cell migration by inducing MMP-9 expression through CCR5 via activation of PLC→PKCδ→NF-κB signaling. MMP-9 siRNA abrogates CCL5-induced migration, placing MMP-9 downstream of CCL5/CCR5 in this pathway.","method":"RT-PCR, flow cytometry, siRNA (MMP-9), specific pharmacological inhibitors (PLC, PKCδ, NF-κB), migration and invasion assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown combined with pharmacological pathway dissection, single lab","pmids":["19334035"],"is_preprint":false},{"year":2017,"finding":"RANTES/CCL5 induces MMP-1 and MMP-13 expression in rheumatoid arthritis synovial fibroblasts (RASFs) through PKCδ, JNK, and ERK signaling, leading to collagenase activity and collagen triple-helix degradation. Heparan sulfate proteoglycan (HSPG) digestion by heparinase III or Met-RANTES pre-treatment completely abrogates MMP induction. CCL5 siRNA also reduces IL-1β-induced MMP expression, placing CCL5 upstream of IL-1β-driven MMP production.","method":"3D micromass culture, collagenase activity assay, circular dichroism spectroscopy, siRNA, Met-RANTES antagonist, heparinase III, specific kinase inhibitors","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (siRNA, enzyme digestion, inhibitors, structural assay), single lab","pmids":["29093715"],"is_preprint":false},{"year":2012,"finding":"Rantes/CCL5 influences hematopoietic stem cell (HSC) subtype distribution and causes myeloid skewing. Forced CCL5 overexpression reduced T-cell output; brief ex vivo CCL5 exposure decreased T-cell progeny and increased myeloid progenitors. CCL5 knockout mice show decreased myeloid-biased HSCs and myeloid progenitors, increased lymphoid-biased HSCs, and decreased mTOR activity in KLS cells.","method":"Retroviral overexpression, knockout mice, transplantation assays, flow cytometry, mTOR activity measurement","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with defined cellular phenotypes, single lab","pmids":["22289892"],"is_preprint":false},{"year":2015,"finding":"CCL5 released by activated platelets (via TRAP stimulation) increases megakaryocyte (MK) proplatelet formation and ploidy through CCR5. Maraviroc (CCR5 antagonist) or CCL5 immunodepletion of platelet releasate abolished most of this effect. Mechanistically, CCL5/CCR5 may increase MK ploidy and proplatelet formation by suppressing apoptosis through the Akt signaling pathway.","method":"MK culture with platelet releasate, recombinant CCL5, maraviroc, CCL5 immunodepletion, ploidy measurements, Akt signaling assays, in vivo murine colitis model","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and immunodepletion approaches with in vitro and in vivo confirmation, single lab","pmids":["26647394"],"is_preprint":false},{"year":2014,"finding":"The Fli-1 transcription factor (Ets family) directly binds Ets binding sites in the distal CCL5 promoter and drives CCL5 transcription in a dose-dependent manner. Fli-1 knockdown (siRNA) in endothelial cells significantly decreased CCL5 protein. Ets1 acts as a dominant-negative for Fli-1 at shared binding sites. A 225-bp region of the CCL5 promoter contains the critical Fli-1 binding sites.","method":"ChIP, siRNA knockdown, transient transfection with promoter-reporter constructs, promoter deletion and mutation analysis","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, siRNA, and reporter assays, single lab","pmids":["25098295"],"is_preprint":false},{"year":2014,"finding":"YB-1 phosphorylated at Ser-102 (mediated through Akt signaling) binds the CCL5 promoter with greater affinity and trans-activates CCL5 expression during monocyte differentiation. Calcineurin (CN) dephosphorylates YB-1 at Ser-102, preventing its binding to the CCL5 promoter and thereby downregulating CCL5. Co-immunoprecipitation confirmed a direct YB-1/CN interaction.","method":"Co-immunoprecipitation, promoter-reporter assays, Akt pathway inhibitors, calcineurin inhibitor (cyclosporine A), ChIP, in vivo mouse kidney tissue analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, promoter assay, and in vivo validation, single lab","pmids":["24947514"],"is_preprint":false},{"year":2007,"finding":"Activation of Nod1 and Nod2 (intracellular pattern recognition receptors) induces CCL5 secretion in murine macrophages via the NF-κB pathway (not via interferon-β signaling). In vivo, intraperitoneal injection of Nod1 or Nod2 agonists rapidly elevates CCL5 in blood. NF-κB was identified as the key signaling pathway by promoter stimulation assays.","method":"Macrophage stimulation assays, in vivo agonist injection, promoter-reporter assays, NF-κB pathway analysis","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo experiments with promoter validation, single lab","pmids":["17705131"],"is_preprint":false},{"year":2020,"finding":"ASIC1a (acid-sensing ion channel 1a) mediates Ca2+ influx in rheumatoid arthritis synovial fibroblasts, which activates NFATc3 nuclear translocation. NFATc3 then directly binds the RANTES/CCL5 promoter and activates CCL5 transcription, as shown by ChIP-qPCR and dual-luciferase reporter assay.","method":"Calcium imaging, flow cytometry, ChIP-qPCR, dual-luciferase reporter assay, Western blot, immunofluorescence, adjuvant-induced arthritis rat model","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays establishing direct promoter binding, supported by in vivo model, single lab","pmids":["31903118"],"is_preprint":false},{"year":2005,"finding":"EBV latent membrane protein 1 (LMP-1) transactivates CCL5 expression via both CTAR-1 and CTAR-2 domains through NF-κB signaling. Dominant-negative constructs for IκBα, IκBβ, IKKα, IKKβ, NIK, and TRAF2 inhibited LMP-1-driven CCL5 promoter activation. The NF-κB binding sites (R(A/B)) at positions -71 to -43 of the CCL5 promoter are essential.","method":"CCL5 promoter-reporter assays, dominant-negative NF-κB pathway constructs, RT-PCR, ELISA in EBV-infected and EBV-negative cell lines","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mapping with dominant-negative constructs, single lab","pmids":["15609310"],"is_preprint":false},{"year":2012,"finding":"CCL5 expression in vascular smooth muscle cells (SMCs) following arterial injury is mediated by IRF-1 binding to an IRF-1 response element in the CCL5 promoter. p38 MAPK suppresses CCL5 expression through MKK3, and the downstream molecule MK2 selectively mediates p38-dependent CCL5 (but not IP-10) inhibition in SMCs.","method":"Balloon artery injury model in rats, SMC culture, promoter-reporter assays, qRT-PCR, pharmacological inhibitors (p38 MAPK, MKK3), MK2 knockdown","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter assay identifying IRF-1 site combined with kinase pathway analysis in vitro and in vivo, single lab","pmids":["22292067"],"is_preprint":false},{"year":2004,"finding":"IL-1 induces RANTES/CCL5 expression in human astrocytes through NF-κB, p38 MAPK, and JNK pathways (but not ERK). IFNβ synergizes with IL-1 by enhancing p38 phosphorylation and by co-inducing nuclear C/EBPβ and ISRE complexes containing Stat1, Stat2, and IRF-1. Mutated promoter-reporter constructs implicated κB, ISRE, and C/EBPβ sites as necessary for IL-1/IFNβ-induced CCL5 transcription.","method":"RNase protection assay, ELISA, promoter-reporter constructs with site mutations, pharmacological inhibitors (p38, JNK, ERK), super-repressor IκBα transfection, EMSA for nuclear complexes","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mapping with multiple mutants and pathway inhibitors, single lab","pmids":["15228586"],"is_preprint":false},{"year":2002,"finding":"HIV-1 Vpr and Nef are required for RANTES/CCL5 induction in primary human microglia. Inhibition of reverse transcription (AZT) blocked CCL5 induction, indicating that productive viral replication is necessary. p38 MAPK plays a negative regulatory role (its specific inhibitor SB203580 augmented CCL5 expression).","method":"HIV infection of primary microglia with accessory gene mutants, AZT reverse transcriptase inhibitor, p38 MAPK inhibitor (SB203580), RT-PCR and protein assays","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — viral mutant panel with pharmacological dissection, single lab","pmids":["12359436"],"is_preprint":false},{"year":2006,"finding":"CCL5/CCR5 signaling in microglia activates intracellular Ca2+ elevation through a multi-step pathway requiring JAK activity, inhibitory G protein, PI3K, Bruton's tyrosine kinase, PLC-mediated IP3-sensitive Ca2+ store release, and NAD metabolites (cADPR for intracellular Ca2+ release; ADPR for Ca2+ influx via a nimodipine-sensitive channel).","method":"Fura-2 digital imaging of [Ca2+]i, pharmacological inhibitors targeting each step (JAK, Gi, PI3K, Btk, PLC), cADPR and ADPR application, nimodipine block","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic pharmacological dissection with multiple inhibitors targeting distinct pathway steps, single lab","pmids":["16547971"],"is_preprint":false},{"year":2021,"finding":"CCL5 secreted by pericytes activates CCR5 on GBM cells to enable DNA-PKcs-mediated DNA damage repair (DDR) upon temozolomide treatment. Disrupting CCL5-CCR5 paracrine signaling with maraviroc inhibits pericyte-promoted DDR and enhances TMZ cytotoxicity in GBM xenografts.","method":"Genetic pericyte depletion in xenografts, CCR5 antagonist (maraviroc), DNA-PKcs activity assays, GBM patient-derived xenografts, in vivo survival experiments","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic depletion plus pharmacological inhibition with mechanistic DDR readout in vivo, single lab","pmids":["34239070"],"is_preprint":false},{"year":2016,"finding":"CCL5/CCR5 promotes angiogenic effects that depend on VEGF secretion by endothelial cells, CCR1 and CCR5 receptor signaling, and GAG (heparan sulfate proteoglycan) binding via SDC-1, SDC-4, and CD44. CCL5 mutants impaired in oligomerization ([E66A]) or GAG binding ([44AANA47]) fail to induce angiogenic effects in vitro and in vivo, establishing that both oligomerization and GAG binding are required for RANTES/CCL5-induced angiogenesis.","method":"In vitro endothelial migration/spreading/tube formation assays, in vivo rat subcutaneous neovascularization model, anti-VEGF receptor antibodies, CCL5 mutants ([E66A], [44AANA47]), siRNA for SDC-1/SDC-4, MMP-9 activity assays","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo with CCL5 mutants and siRNA, single lab","pmids":["22752444"],"is_preprint":false},{"year":2014,"finding":"IL-32θ downregulates CCL5 expression by interacting with PKCδ and STAT3. This interaction leads to STAT3 phosphorylation at Ser727, rendering STAT3 transcriptionally inactive at the CCL5 promoter. Co-IP and pulldown assays confirmed direct IL-32θ/PKCδ and IL-32θ/STAT3 interactions.","method":"Co-immunoprecipitation, pulldown assay, ELISA, STAT3 Ser727 phosphorylation assay, ChIP for STAT3 at CCL5 promoter","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and pulldown establishing protein interactions with ChIP for promoter occupancy, single lab","pmids":["25280942"],"is_preprint":false},{"year":2021,"finding":"Tristetraprolin (TTP) promotes N6-methyladenosine (m6A) methylation on CCL5 mRNA, destabilizing it and reducing CCL5 levels. TTP overexpression upregulates m6A methylation enzymes (WTAP, METTL14, YTHDF2), globally increasing m6A and specifically decreasing CCL5 mRNA stability, ameliorating acute liver failure in vivo.","method":"m6A sequencing, RNA stability assays, TTP overexpression in vivo, methyltransferase expression analysis, in vivo murine acute liver failure model","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with m6A mechanistic readout in vitro and in vivo, single lab","pmids":["34877932"],"is_preprint":false},{"year":2016,"finding":"CCL5/RANTES contributes to hypothalamic insulin signaling through CCR5, which co-localizes and co-immunoprecipitates with insulin receptors in the arcuate nucleus. CCL5/CCR5 activates the PI3K-Akt pathway and reduces inhibitory phosphorylation of IRS-1 at Ser302 via AMPKα-S6 kinase signaling, promoting GLUT4 membrane translocation. Intracerebroventricular Met-CCL5 blocks hypothalamic insulin signaling and induces peripheral glucose intolerance.","method":"Co-immunoprecipitation, immunostaining, ex vivo and in vitro stimulation assays, CCR5/CCL5 knockout mice, GLUT4 translocation assay, intracerebroventricular drug delivery","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, knockout mice with defined metabolic phenotypes, and pharmacological validation, single lab","pmids":["27898058"],"is_preprint":false},{"year":2021,"finding":"CCL5 supports hippocampal synaptic function and memory formation by promoting bioenergy metabolism: fructose/mannose degradation, glycolysis, gluconeogenesis, glutamate and purine metabolism, ATP generation, and mitochondrial structural integrity. Re-expressing CCL5 in CCL5-knockout mouse hippocampus restored synaptic protein expression, neuronal connectivity, and cognitive function.","method":"CCL5 knockout mice, hippocampal LTP measurement, metabolomics, FDG-PET imaging, Seahorse metabolic analysis, AAV re-expression, behavioral assays","journal":"Molecular psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal metabolic and functional readouts with rescue experiment, single lab","pmids":["33931731"],"is_preprint":false},{"year":2000,"finding":"RANTES expression in T lymphocytes requires the Krüppel-like transcription factor RFLAT-1 (KLF13), which is itself expressed late after T-cell activation. Uniquely, RFLAT-1 expression is translationally rather than transcriptionally regulated, explaining the 3–5 day delayed kinetics of RANTES expression in activated T cells.","method":"Promoter characterization, transcription factor identification and characterization, T-cell activation time-course experiments","journal":"Immunological reviews","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — identification and characterization of a novel regulator with defined promoter function, single lab","pmids":["11138780"],"is_preprint":false},{"year":1993,"finding":"The RANTES gene spans ~7.1 kb with three exons and two introns, and has a 1-kb promoter containing consensus elements for T cell/hematopoietic, myeloid, muscle, and ubiquitous transcription factors. Promoter-luciferase assays and deletion analysis show that different transcriptional mechanisms regulate RANTES expression in different cell types (e.g., high in mature T cells Hut78 but not in early T cell lines), and that the kinetics of RANTES mRNA expression differ between cell types (late in T cells, early in fibroblasts/epithelial cells after TNF-α).","method":"Gene sequencing, promoter-luciferase reporter assays, deletion analysis, Northern blot","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter-reporter assays with deletion analysis in multiple cell types, single lab","pmids":["7689610"],"is_preprint":false},{"year":2021,"finding":"CCL5 inhibits influenza A virus (IAV) replication in alveolar epithelial cells by upregulating the restriction factor SAMHD1. CCL5-mediated SAMHD1 upregulation is dependent on PKC signaling. SAMHD1 knockdown abolishes both CCL5-mediated IAV inhibition and CCL5-mediated cell death inhibition.","method":"A549 cell CCR5 stimulation with CCL5, RT-PCR restriction factor panel, siRNA knockdown of SAMHD1, PKC inhibition, viral titer assays","journal":"Frontiers in cellular and infection microbiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, CCL5-treated cells with siRNA knockdown but indirect mechanism (SAMHD1 as mediator not directly shown for endogenous CCL5 signaling)","pmids":["34490131"],"is_preprint":false},{"year":1998,"finding":"RANTES induces a biphasic Ca2+ signal in T cells: an early G protein-mediated phase associated with chemotaxis, and a late tyrosine kinase-linked phase unique to RANTES. The late phase correlates with CD3 expression on Jurkat T cells, and prior TCR stimulation with anti-CD3 suppresses the RANTES-induced second phase, suggesting TCR involvement.","method":"Ca2+ flux measurements, Jurkat cell sorting by CD3 expression, anti-CD3 mAb stimulation, comparison of CD3-high vs. CD3-low populations","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, correlation between CD3 expression and RANTES response with limited mechanistic follow-up","pmids":["9552000"],"is_preprint":false},{"year":2009,"finding":"CCL5 promotes macrophage survival in adipose tissue by protecting macrophages from free cholesterol-induced apoptosis via activation of Akt and ERK pathways. CCL5 also triggers adhesion and transmigration of blood monocytes through adipose tissue endothelial cells.","method":"Macrophage apoptosis assays (free cholesterol model), Akt/ERK pathway activation assays, monocyte transmigration assay through adipose tissue endothelial cells","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional cellular assays without deep pathway dissection or genetic validation, single lab","pmids":["19893003"],"is_preprint":false}],"current_model":"CCL5 (RANTES) is a secreted CC-chemokine that acts primarily through G protein-coupled receptors CCR1, CCR3, and CCR5, but also through a GPCR-independent pathway via CD44–glycosaminoglycan (GAG) interaction that activates Src kinases and p44/42 MAPK; CCL5 undergoes higher-order oligomerization (forming double-helical rod-shaped polymers) that, together with GAG/heparan sulfate proteoglycan binding via a KKWVR motif, is essential for immobilization on endothelial surfaces, leukocyte arrest under flow, induction of apoptosis in T cells, and pro-angiogenic activity; its transcription is regulated by NF-κB (downstream of Nod1/2, LMP-1, IL-1, TNF-α), IRF-1, Fli-1/Ets family factors, KLF13/RFLAT-1 (translationally controlled in T cells), NFATc3 (downstream of Ca2+ influx via ASIC1a), and YB-1 (controlled by Akt-mediated phosphorylation and calcineurin-mediated dephosphorylation); CCL5 mRNA stability is regulated by TTP-mediated m6A methylation; and downstream of CCR5, CCL5 drives cell migration via MEK/ERK/NF-κB/integrin, PKCδ/JNK/ERK/MMP, and PI3K/Akt/GLUT4 pathways in different cell types, while also supporting hypothalamic insulin signaling, hippocampal synaptic bioenergetics, and pericyte-driven DNA-PKcs-mediated chemoresistance in glioblastoma."},"narrative":{"mechanistic_narrative":"CCL5 (RANTES) is a secreted CC-chemokine that orchestrates leukocyte recruitment, inflammation, and tissue remodeling through receptor engagement coupled to glycosaminoglycan (GAG)-dependent surface presentation [PMID:27091995, PMID:11282909]. Structurally, CCL5 polymerizes into rod-shaped, double-helical higher-order oligomers, and oligomerization is functionally separable from GAG binding: oligomers engage GAGs through a positively charged KKWVR motif distinct from the BBXB motif used by monomers/dimers, while NMR shows dimer-GAG contacts also extend to the N loop in a sulfation-dependent manner [PMID:27091995, PMID:25982530]. This higher-order assembly is required for the regular, heparan sulfate-dependent filamentous deposition of CCL5 on endothelial surfaces that enables shear-resistant monocyte arrest under flow, with platelet-derived CCL5 immobilized on activated and atherosclerotic endothelium [PMID:25791723, PMID:11282909]. The same oligomerization- and GAG-dependent logic governs CCL5-induced T-cell apoptosis (requiring CCR5, its Tyr339, and surface GAGs, with caspase-9/-3 activation and cytochrome c release) and pro-angiogenic activity dependent on syndecan-1/-4 and CD44 and on VEGF secretion [PMID:16807236, PMID:22752444]. CCL5 signals canonically through CCR5 (and CCR1/CCR3), where early Ca2+ and JAK/STAT responses are separable from late FAK-dependent polarization and chemotaxis [PMID:10037796], and additionally through a GPCR-independent route via CD44-GAG that assembles a CD44/Src complex activating p44/42 MAPK [PMID:12714503]. Downstream of CCR5/CCR1, CCL5 drives migration, invasion, and matrix remodeling across cell types via MEK/ERK/NF-κB-driven αvβ3 integrin induction, PLC/PKCδ/NF-κB-driven MMP-9, and PKCδ/JNK/ERK-driven MMP-1/MMP-13 collagenase activity [PMID:22506069, PMID:19334035, PMID:29093715]. Beyond inflammation, CCL5/CCR5 supports hematopoietic stem cell myeloid skewing, megakaryocyte proplatelet formation, hypothalamic insulin signaling and GLUT4 translocation, hippocampal synaptic bioenergetics, and pericyte-driven DNA-PKcs-mediated chemoresistance in glioblastoma [PMID:22289892, PMID:26647394, PMID:27898058, PMID:33931731, PMID:34239070]. CCL5 transcription is controlled in a cell-type- and stimulus-specific manner by NF-κB (downstream of Nod1/2, EBV LMP-1, and IL-1), IRF-1, the Ets factor Fli-1, KLF13/RFLAT-1 (translationally regulated in T cells), NFATc3 (downstream of ASIC1a-mediated Ca2+ influx), and Akt-phosphorylated YB-1, while m6A methylation promoted by tristetraprolin destabilizes CCL5 mRNA [PMID:17705131, PMID:15609310, PMID:15228586, PMID:22292067, PMID:25098295, PMID:11138780, PMID:31903118, PMID:24947514, PMID:34877932].","teleology":[{"year":1993,"claim":"Establishing the RANTES gene structure and promoter defined that its expression is cell-type-specific and kinetically distinct, framing the question of which factors drive transcription in each context.","evidence":"Gene sequencing, promoter-luciferase deletion analysis, and Northern blot across T-cell, fibroblast, and epithelial lines","pmids":["7689610"],"confidence":"Medium","gaps":["Individual transcription factors binding the mapped elements were not identified","Kinetic differences between cell types were described but not mechanistically explained"]},{"year":1998,"claim":"Resolving how CCL5 signals in T cells showed a biphasic Ca2+ response, separating a chemotactic G protein phase from a late tyrosine kinase phase linked to TCR/CD3.","evidence":"Ca2+ flux in CD3-sorted Jurkat cells with anti-CD3 stimulation","pmids":["9552000"],"confidence":"Low","gaps":["Correlation between CD3 expression and the late phase, not a defined mechanism","Molecular link between TCR and CCL5 signaling not established"]},{"year":2000,"claim":"Identifying RFLAT-1/KLF13 as a translationally regulated activator explained the delayed kinetics of RANTES expression in activated T cells.","evidence":"Promoter characterization and T-cell activation time-course","pmids":["11138780"],"confidence":"Medium","gaps":["Mechanism of translational control of KLF13 not detailed","Cooperation with other promoter factors unresolved"]},{"year":2001,"claim":"Demonstrating that platelet-derived RANTES is immobilized on activated endothelium and triggers shear-resistant monocyte arrest connected CCL5 deposition to atherogenic leukocyte recruitment in vivo.","evidence":"Flow chamber video microscopy, Met-RANTES inhibition, ApoE-/- immunohistochemistry, ex vivo carotid perfusion","pmids":["11282909"],"confidence":"High","gaps":["Molecular basis of endothelial immobilization (GAG/oligomer requirement) not yet defined here","Receptor mediating arrest not specified"]},{"year":2002,"claim":"Mapping HIV-1 induction of CCL5 in microglia showed productive replication and Vpr/Nef are required, with p38 acting as a negative regulator.","evidence":"HIV accessory gene mutants, AZT, and p38 inhibitor in primary microglia","pmids":["12359436"],"confidence":"Medium","gaps":["Direct transcription factor link not established","Generalizability beyond microglia unknown"]},{"year":2003,"claim":"Discovery of a GPCR-independent CCL5 pathway through CD44-GAG that assembles a CD44/Src complex activating p44/42 MAPK established a receptor-independent signaling axis.","evidence":"Reciprocal Co-IP, CD44 RNAi, MAPK phosphorylation, and HIV infectivity assays","pmids":["12714503"],"confidence":"High","gaps":["Downstream consequences of CD44/Src signaling beyond MAPK and HIV enhancement not mapped","Physiological contexts using this pathway not defined"]},{"year":1999,"claim":"Pharmacological dissection of CCR5 signaling separated early responses (Ca2+, dimerization, JAK/STAT) from late FAK-dependent polarization and chemotaxis, showing late events are required for migration.","evidence":"CCR5-transfected HEK-293 cells with (AOP)-RANTES and FAK Co-IP and chemotaxis assays","pmids":["10037796"],"confidence":"High","gaps":["Molecular trigger distinguishing early vs late signaling not identified","Endogenous receptor context not tested"]},{"year":2004,"claim":"Defining IL-1/IFNβ induction of CCL5 in astrocytes through NF-κB, p38, JNK, and synergistic ISRE/C/EBPβ complexes identified the cytokine-driven transcriptional circuitry.","evidence":"Promoter-reporter mutants, pathway inhibitors, super-repressor IκBα, and EMSA","pmids":["15228586"],"confidence":"Medium","gaps":["Relative contribution of each element in vivo not assessed","Cell-type specificity beyond astrocytes unresolved"]},{"year":2005,"claim":"Showing EBV LMP-1 transactivates CCL5 via CTAR domains and NF-κB through defined promoter sites linked viral oncoprotein signaling to CCL5 induction.","evidence":"Promoter-reporter assays with dominant-negative NF-κB pathway constructs","pmids":["15609310"],"confidence":"Medium","gaps":["In vivo relevance in EBV-associated disease not established","Interplay with other LMP-1-induced genes not addressed"]},{"year":2006,"claim":"Establishing that CCL5-induced T-cell apoptosis requires CCR5 Tyr339, surface GAGs, and higher-order oligomerization tied the chemokine's structural assembly directly to a death-inducing function.","evidence":"CCR5 and ligand structure-function mutants with caspase and cytochrome c readouts","pmids":["16807236"],"confidence":"High","gaps":["Signaling steps linking oligomerized CCL5 to mitochondrial apoptosis not fully mapped","Physiological setting of T-cell killing not defined"]},{"year":2006,"claim":"Dissecting CCL5/CCR5-evoked Ca2+ signaling in microglia revealed a multi-step JAK/Gi/PI3K/Btk/PLC cascade using cADPR and ADPR as second messengers.","evidence":"Fura-2 imaging with systematic pharmacological inhibition and nucleotide application","pmids":["16547971"],"confidence":"Medium","gaps":["Direct molecular targets of cADPR/ADPR not identified","Functional output of the Ca2+ signal not defined"]},{"year":2009,"claim":"Characterizing CCL5-driven migration in multiple cancer types established proteoglycan co-receptors (syndecan-1/-4) and PKCδ/NF-κB-driven MMP-9 as effectors of invasion.","evidence":"RNAi of SDC-1/SDC-4 and MMP-9, GAG-binding-deficient CCL5 mutants, and pathway inhibitors in hepatoma and oral cancer cells","pmids":["19632304","19334035"],"confidence":"Medium","gaps":["Whether these pathways operate in primary tumors not shown","Receptor selectivity (CCR1 vs CCR5) context-dependent"]},{"year":2009,"claim":"Linking CCL5 to macrophage survival and monocyte transmigration in adipose tissue extended its role to metabolic-tissue inflammation.","evidence":"Macrophage apoptosis and transmigration assays with Akt/ERK readouts","pmids":["19893003"],"confidence":"Low","gaps":["No genetic validation or deep pathway dissection","Receptor mediating the effect not defined"]},{"year":2012,"claim":"Multiple gain/loss-of-function studies defined CCL5 transcriptional regulators and a hematopoietic role, including IRF-1-driven expression in injured vessels and CCL5-dependent myeloid skewing of HSCs.","evidence":"IRF-1 promoter mapping with p38/MKK3/MK2 dissection in injured arteries; CCL5 overexpression and knockout mice in HSC transplantation","pmids":["22292067","22289892"],"confidence":"Medium","gaps":["Direct receptor for the HSC effect not identified","Connection between transcriptional control and hematopoietic phenotype not integrated"]},{"year":2012,"claim":"Showing CCL5/CCR5 induces αvβ3 integrin via MEK/ERK/NF-κB and contributes GAG- and oligomerization-dependent angiogenesis tied receptor signaling and structural assembly to tumor-relevant cell behaviors.","evidence":"siRNA/inhibitor migration assays in osteosarcoma; CCL5 mutants, SDC siRNA, anti-VEGFR antibodies in angiogenesis models","pmids":["22506069","22752444"],"confidence":"Medium","gaps":["Integration of GPCR and GAG inputs during angiogenesis unresolved","In vivo tumor angiogenesis relevance limited to single models"]},{"year":2014,"claim":"Identifying Fli-1, Akt-phosphorylated YB-1 (countered by calcineurin), and IL-32θ/PKCδ/STAT3 as regulators expanded the CCL5 transcriptional network and its post-translational control.","evidence":"ChIP, siRNA, promoter-reporter, and Co-IP across endothelial, monocyte, and other systems","pmids":["25098295","24947514","25280942"],"confidence":"Medium","gaps":["Hierarchy among these factors not established","Combinatorial control in a single cell type not tested"]},{"year":2015,"claim":"High-resolution structural work defined how CCL5 dimers and oligomers contact GAGs and established that filamentous endothelial deposition requires both higher-order oligomerization and heparan sulfate binding.","evidence":"Solution NMR with PRE/NOE constraints; EM/IF/flow chamber with oligomerization and GAG-binding mutants","pmids":["25982530","25791723"],"confidence":"High","gaps":["Dynamics of polymer assembly on living endothelium not directly observed","Link from filament geometry to specific receptor engagement not resolved"]},{"year":2015,"claim":"Demonstrating that platelet-released CCL5 increases megakaryocyte proplatelet formation and ploidy through CCR5/Akt extended CCL5 function to thrombopoiesis.","evidence":"MK culture with releasate, maraviroc, CCL5 immunodepletion, and an in vivo colitis model","pmids":["26647394"],"confidence":"Medium","gaps":["Direct CCR5 signaling steps to ploidy not fully mapped","Apoptosis-suppression mechanism described as putative"]},{"year":2016,"claim":"Crystal/solution structures resolved CCL5 as a polymerizing chemokine forming double-helical oligomers using a KKWVR GAG-binding motif distinct from the monomer/dimer BBXB motif, making oligomerization and GAG binding structurally separable.","evidence":"X-ray crystallography and biophysics with GAG-binding and oligomerization mutants","pmids":["27091995"],"confidence":"High","gaps":["In vivo dependence of each motif on specific functions not exhaustively tested","Polymer length regulation not defined"]},{"year":2016,"claim":"Identifying CCL5/CCR5 as a positive regulator of hypothalamic insulin signaling via PI3K-Akt and AMPKα-S6K modulation of IRS-1 extended CCL5 into central metabolic control.","evidence":"Co-IP of CCR5 with insulin receptor, knockout mice, GLUT4 translocation, and intracerebroventricular Met-CCL5","pmids":["27898058"],"confidence":"Medium","gaps":["Mechanism of CCR5-insulin receptor cross-talk not structurally defined","Relevance to systemic insulin resistance only partly addressed"]},{"year":2020,"claim":"Establishing the ASIC1a-Ca2+-NFATc3 axis as a direct CCL5 promoter activator linked ion-channel-driven calcium signaling to CCL5 transcription in arthritis.","evidence":"Calcium imaging, ChIP-qPCR, dual-luciferase reporter, and an adjuvant-induced arthritis model","pmids":["31903118"],"confidence":"Medium","gaps":["Cooperation of NFATc3 with NF-κB at the promoter not dissected","Generalizability beyond synovial fibroblasts unknown"]},{"year":2021,"claim":"Multiple studies expanded CCL5 into matrix degradation, RNA-level control, neuronal bioenergetics, antiviral restriction, and tumor chemoresistance, broadening its mechanistic reach.","evidence":"Collagenase/CD/siRNA in RA fibroblasts (MMP-1/-13); m6A-seq and TTP overexpression; CCL5-KO hippocampal metabolomics and rescue; SAMHD1 knockdown in A549; pericyte depletion and maraviroc in GBM xenografts","pmids":["29093715","34877932","33931731","34490131","34239070"],"confidence":"Medium","gaps":["Each role established in a single lab/model","Connections among these diverse functions not integrated"]},{"year":null,"claim":"How CCL5 oligomer geometry, GAG binding, and receptor (CCR1/3/5 vs CD44) engagement are integrated to select among migration, apoptosis, angiogenesis, and metabolic outputs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking structural assembly state to functional output","Quantitative receptor occupancy on GAG-immobilized oligomers in vivo not measured","Cross-talk between GPCR-dependent and CD44-dependent pathways not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[4,5,7,22,26]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,1,2]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,23]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,6,11,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,7,21,26]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[13,14,16,17,19,28]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[3,5]}],"complexes":[],"partners":["CCR5","CCR1","CD44","SDC1","SDC4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P13501","full_name":"C-C motif chemokine 5","aliases":["EoCP","Eosinophil chemotactic cytokine","SIS-delta","Small-inducible cytokine A5","T cell-specific protein P228","TCP228","T-cell-specific protein RANTES"],"length_aa":91,"mass_kda":10.0,"function":"Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) (PubMed:1380064, PubMed:15923218, PubMed:16791620, PubMed:8525373, PubMed:9516414). May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (PubMed:23979485)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P13501/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL5","classification":"Not Classified","n_dependent_lines":16,"n_total_lines":1208,"dependency_fraction":0.013245033112582781},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL5","total_profiled":1310},"omim":[{"mim_id":"613766","title":"SECRETORY CARRIER MEMBRANE PROTEIN 5; SCAMP5","url":"https://www.omim.org/entry/613766"},{"mim_id":"613665","title":"ATYPICAL CHEMOKINE RECEPTOR 1; ACKR1","url":"https://www.omim.org/entry/613665"},{"mim_id":"612672","title":"RAS-ASSOCIATED PROTEIN RAB10; RAB10","url":"https://www.omim.org/entry/612672"},{"mim_id":"611387","title":"CXC CHEMOKINE LIGAND 17; CXCL17","url":"https://www.omim.org/entry/611387"},{"mim_id":"610424","title":"HEPATITIS B VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/610424"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":114.7},{"tissue":"lymphoid tissue","ntpm":126.6}],"url":"https://www.proteinatlas.org/search/CCL5"},"hgnc":{"alias_symbol":["RANTES","SISd","TCP228","MGC17164"],"prev_symbol":["D17S136E","SCYA5"]},"alphafold":{"accession":"P13501","domains":[{"cath_id":"2.40.50.40","chopping":"32-91","consensus_level":"medium","plddt":97.2378,"start":32,"end":91}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13501","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13501-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13501-F1-predicted_aligned_error_v6.png","plddt_mean":88.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL5","jax_strain_url":"https://www.jax.org/strain/search?query=CCL5"},"sequence":{"accession":"P13501","fasta_url":"https://rest.uniprot.org/uniprotkb/P13501.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13501/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13501"}},"corpus_meta":[{"pmid":"18439751","id":"PMC_18439751","title":"The inflammatory chemokines CCL2 and CCL5 in breast cancer.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18439751","citation_count":483,"is_preprint":false},{"pmid":"11282909","id":"PMC_11282909","title":"RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.","date":"2001","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/11282909","citation_count":464,"is_preprint":false},{"pmid":"24523569","id":"PMC_24523569","title":"The inflammatory chemokine CCL5 and cancer progression.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24523569","citation_count":355,"is_preprint":false},{"pmid":"32630699","id":"PMC_32630699","title":"The CCL5/CCR5 Axis in Cancer Progression.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32630699","citation_count":313,"is_preprint":false},{"pmid":"24090198","id":"PMC_24090198","title":"Targeting CCL5 in inflammation.","date":"2013","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/24090198","citation_count":312,"is_preprint":false},{"pmid":"34514075","id":"PMC_34514075","title":"CCL5/CCR5 axis in human diseases and related treatments.","date":"2021","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34514075","citation_count":276,"is_preprint":false},{"pmid":"7689610","id":"PMC_7689610","title":"Genomic organization and transcriptional regulation of the RANTES chemokine gene.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7689610","citation_count":258,"is_preprint":false},{"pmid":"22289892","id":"PMC_22289892","title":"Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22289892","citation_count":228,"is_preprint":false},{"pmid":"11424873","id":"PMC_11424873","title":"MCP-1 and RANTES are mediators of acute and chronic inflammation.","date":"2001","source":"Allergy and asthma proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/11424873","citation_count":219,"is_preprint":false},{"pmid":"11850348","id":"PMC_11850348","title":"Chemokine RANTES in severe pulmonary arterial hypertension.","date":"2002","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11850348","citation_count":207,"is_preprint":false},{"pmid":"16161154","id":"PMC_16161154","title":"Expression of CCL5 (RANTES) and CCR5 in prostate cancer.","date":"2006","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/16161154","citation_count":197,"is_preprint":false},{"pmid":"25901081","id":"PMC_25901081","title":"CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25901081","citation_count":184,"is_preprint":false},{"pmid":"19893003","id":"PMC_19893003","title":"CCL5 promotes macrophage recruitment and survival in human adipose tissue.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19893003","citation_count":181,"is_preprint":false},{"pmid":"34239070","id":"PMC_34239070","title":"Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling.","date":"2021","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34239070","citation_count":134,"is_preprint":false},{"pmid":"17322928","id":"PMC_17322928","title":"Mechanisms of disease: regulation of RANTES (CCL5) in renal disease.","date":"2007","source":"Nature clinical practice. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/17322928","citation_count":116,"is_preprint":false},{"pmid":"16873271","id":"PMC_16873271","title":"Role of CCL5 (RANTES) in viral lung disease.","date":"2006","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16873271","citation_count":111,"is_preprint":false},{"pmid":"8981204","id":"PMC_8981204","title":"RANTES chemokine expression in transplant-associated accelerated atherosclerosis.","date":"1996","source":"The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/8981204","citation_count":109,"is_preprint":false},{"pmid":"9756723","id":"PMC_9756723","title":"RANTES expression and contribution to monocyte chemotaxis in arthritis.","date":"1998","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/9756723","citation_count":107,"is_preprint":false},{"pmid":"10037796","id":"PMC_10037796","title":"Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10037796","citation_count":100,"is_preprint":false},{"pmid":"12714503","id":"PMC_12714503","title":"RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12714503","citation_count":100,"is_preprint":false},{"pmid":"12949794","id":"PMC_12949794","title":"Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12949794","citation_count":96,"is_preprint":false},{"pmid":"19334035","id":"PMC_19334035","title":"CCL5/CCR5 axis promotes the motility of human oral cancer cells.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19334035","citation_count":96,"is_preprint":false},{"pmid":"29093715","id":"PMC_29093715","title":"RANTES/CCL5 Induces Collagen Degradation by Activating MMP-1 and MMP-13 Expression in Human Rheumatoid Arthritis Synovial Fibroblasts.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29093715","citation_count":96,"is_preprint":false},{"pmid":"26647394","id":"PMC_26647394","title":"CCL5 derived from platelets increases megakaryocyte proplatelet formation.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26647394","citation_count":95,"is_preprint":false},{"pmid":"25256399","id":"PMC_25256399","title":"The potential to target CCL5/CCR5 in breast cancer.","date":"2014","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/25256399","citation_count":94,"is_preprint":false},{"pmid":"9536224","id":"PMC_9536224","title":"RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol).","date":"1998","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9536224","citation_count":93,"is_preprint":false},{"pmid":"19665464","id":"PMC_19665464","title":"Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice.","date":"2009","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19665464","citation_count":92,"is_preprint":false},{"pmid":"22506069","id":"PMC_22506069","title":"CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22506069","citation_count":88,"is_preprint":false},{"pmid":"22752444","id":"PMC_22752444","title":"RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans.","date":"2012","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22752444","citation_count":85,"is_preprint":false},{"pmid":"28011329","id":"PMC_28011329","title":"Functional role of CCL5/RANTES for HCC progression during chronic liver disease.","date":"2016","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28011329","citation_count":82,"is_preprint":false},{"pmid":"8742071","id":"PMC_8742071","title":"RANTES chemokine expression in diseased and normal human tissues.","date":"1996","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/8742071","citation_count":81,"is_preprint":false},{"pmid":"32511656","id":"PMC_32511656","title":"Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.","date":"2020","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32511656","citation_count":81,"is_preprint":false},{"pmid":"20233026","id":"PMC_20233026","title":"CCL5 as an adjuvant for cancer immunotherapy.","date":"2010","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20233026","citation_count":77,"is_preprint":false},{"pmid":"11138780","id":"PMC_11138780","title":"Transcriptional regulation of RANTES expression in T lymphocytes.","date":"2000","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11138780","citation_count":77,"is_preprint":false},{"pmid":"24500793","id":"PMC_24500793","title":"CCL5/RANTES is a key chemoattractant released by degenerative intervertebral discs in organ culture.","date":"2014","source":"European cells & materials","url":"https://pubmed.ncbi.nlm.nih.gov/24500793","citation_count":77,"is_preprint":false},{"pmid":"1691736","id":"PMC_1691736","title":"Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11.2-q12.","date":"1990","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1691736","citation_count":72,"is_preprint":false},{"pmid":"17705131","id":"PMC_17705131","title":"Nod1 and Nod2 induce CCL5/RANTES through the NF-kappaB pathway.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17705131","citation_count":69,"is_preprint":false},{"pmid":"22103502","id":"PMC_22103502","title":"Angiogenic properties of the chemokine RANTES/CCL5.","date":"2011","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22103502","citation_count":67,"is_preprint":false},{"pmid":"11000125","id":"PMC_11000125","title":"Inducible lung-specific expression of RANTES: preferential recruitment of neutrophils.","date":"2000","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11000125","citation_count":66,"is_preprint":false},{"pmid":"27091995","id":"PMC_27091995","title":"Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27091995","citation_count":66,"is_preprint":false},{"pmid":"8982121","id":"PMC_8982121","title":"Induction of RANTES expression by astrocytes and astrocytoma cell lines.","date":"1996","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/8982121","citation_count":66,"is_preprint":false},{"pmid":"17641205","id":"PMC_17641205","title":"CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17641205","citation_count":65,"is_preprint":false},{"pmid":"31747383","id":"PMC_31747383","title":"Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.","date":"2019","source":"Radiology and oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31747383","citation_count":63,"is_preprint":false},{"pmid":"11466387","id":"PMC_11466387","title":"RANTES-induced chemokine cascade in dendritic cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11466387","citation_count":63,"is_preprint":false},{"pmid":"16807236","id":"PMC_16807236","title":"CCL5-CCR5-mediated apoptosis in T cells: Requirement for glycosaminoglycan binding and CCL5 aggregation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16807236","citation_count":62,"is_preprint":false},{"pmid":"31903118","id":"PMC_31903118","title":"ASIC1a induces synovial inflammation via the Ca2+/NFATc3/ RANTES pathway.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31903118","citation_count":61,"is_preprint":false},{"pmid":"26420723","id":"PMC_26420723","title":"Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.","date":"2015","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26420723","citation_count":61,"is_preprint":false},{"pmid":"26377571","id":"PMC_26377571","title":"RANTES and SDF-1 Are Keys in Cell-based Therapy of TMJ Osteoarthritis.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/26377571","citation_count":60,"is_preprint":false},{"pmid":"28132854","id":"PMC_28132854","title":"Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28132854","citation_count":54,"is_preprint":false},{"pmid":"12112372","id":"PMC_12112372","title":"RANTES stimulates inflammatory cascades and receptor modulation in murine astrocytes.","date":"2002","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/12112372","citation_count":53,"is_preprint":false},{"pmid":"9357137","id":"PMC_9357137","title":"Switching gears during T-cell maturation: RANTES and late transcription.","date":"1997","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/9357137","citation_count":53,"is_preprint":false},{"pmid":"15228586","id":"PMC_15228586","title":"Regulation of RANTES/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta.","date":"2004","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15228586","citation_count":51,"is_preprint":false},{"pmid":"18815890","id":"PMC_18815890","title":"CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice.","date":"2008","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18815890","citation_count":47,"is_preprint":false},{"pmid":"11435978","id":"PMC_11435978","title":"Rantes production during development of cardiac allograft vasculopathy.","date":"2001","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/11435978","citation_count":47,"is_preprint":false},{"pmid":"37185233","id":"PMC_37185233","title":"Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37185233","citation_count":46,"is_preprint":false},{"pmid":"31855281","id":"PMC_31855281","title":"EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer.","date":"2020","source":"Biotechnology and applied biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31855281","citation_count":44,"is_preprint":false},{"pmid":"19632304","id":"PMC_19632304","title":"Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19632304","citation_count":44,"is_preprint":false},{"pmid":"26733422","id":"PMC_26733422","title":"RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis.","date":"2016","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26733422","citation_count":44,"is_preprint":false},{"pmid":"12234296","id":"PMC_12234296","title":"Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12234296","citation_count":43,"is_preprint":false},{"pmid":"12359436","id":"PMC_12359436","title":"Vpr- and Nef-dependent induction of RANTES/CCL5 in microglial cells.","date":"2002","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/12359436","citation_count":42,"is_preprint":false},{"pmid":"10495789","id":"PMC_10495789","title":"Regulation of RANTES and ICAM-1 expression in murine mesangial cells.","date":"1997","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/10495789","citation_count":42,"is_preprint":false},{"pmid":"35033156","id":"PMC_35033156","title":"Macrophages-aPKCɩ-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35033156","citation_count":42,"is_preprint":false},{"pmid":"22162987","id":"PMC_22162987","title":"RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22162987","citation_count":42,"is_preprint":false},{"pmid":"9552000","id":"PMC_9552000","title":"RANTES-induced T cell activation correlates with CD3 expression.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9552000","citation_count":41,"is_preprint":false},{"pmid":"27898058","id":"PMC_27898058","title":"CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CCR5.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27898058","citation_count":40,"is_preprint":false},{"pmid":"25982530","id":"PMC_25982530","title":"Interactions of the Chemokine CCL5/RANTES with Medium-Sized Chondroitin Sulfate Ligands.","date":"2015","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25982530","citation_count":39,"is_preprint":false},{"pmid":"34298673","id":"PMC_34298673","title":"Tumor Extracellular Vesicles Regulate Macrophage-Driven Metastasis through CCL5.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34298673","citation_count":39,"is_preprint":false},{"pmid":"33931731","id":"PMC_33931731","title":"CCL5 promotion of bioenergy metabolism is crucial for hippocampal synapse complex and memory formation.","date":"2021","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/33931731","citation_count":38,"is_preprint":false},{"pmid":"30519117","id":"PMC_30519117","title":"Osteoimmunology of tumor necrosis factor-alpha, IL-6, and RANTES/CCL5: a review of known and poorly understood inflammatory patterns in osteonecrosis.","date":"2018","source":"Clinical, cosmetic and investigational dentistry","url":"https://pubmed.ncbi.nlm.nih.gov/30519117","citation_count":38,"is_preprint":false},{"pmid":"25098295","id":"PMC_25098295","title":"The Fli-1 transcription factor regulates the expression of CCL5/RANTES.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25098295","citation_count":37,"is_preprint":false},{"pmid":"25030847","id":"PMC_25030847","title":"CCL5/RANTES is important for inducing osteogenesis of human mesenchymal stem cells and is regulated by dexamethasone.","date":"2014","source":"Bioscience trends","url":"https://pubmed.ncbi.nlm.nih.gov/25030847","citation_count":37,"is_preprint":false},{"pmid":"21719482","id":"PMC_21719482","title":"IκBα glutathionylation and reduced histone H3 phosphorylation inhibit eotaxin and RANTES.","date":"2011","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/21719482","citation_count":36,"is_preprint":false},{"pmid":"36440924","id":"PMC_36440924","title":"Targeting CCL5 signaling attenuates neuroinflammation after seizure.","date":"2022","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36440924","citation_count":35,"is_preprint":false},{"pmid":"18426815","id":"PMC_18426815","title":"RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.","date":"2008","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18426815","citation_count":35,"is_preprint":false},{"pmid":"24947514","id":"PMC_24947514","title":"Calcineurin-mediated YB-1 dephosphorylation regulates CCL5 expression during monocyte differentiation.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24947514","citation_count":35,"is_preprint":false},{"pmid":"22962966","id":"PMC_22962966","title":"Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific.","date":"2012","source":"Virology journal","url":"https://pubmed.ncbi.nlm.nih.gov/22962966","citation_count":35,"is_preprint":false},{"pmid":"16455992","id":"PMC_16455992","title":"CCL5 modulates pneumococcal immunity and carriage.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16455992","citation_count":33,"is_preprint":false},{"pmid":"16528011","id":"PMC_16528011","title":"RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge.","date":"2006","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16528011","citation_count":33,"is_preprint":false},{"pmid":"15975820","id":"PMC_15975820","title":"IL-17 reduces TNF-induced Rantes and VCAM-1 expression.","date":"2005","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/15975820","citation_count":33,"is_preprint":false},{"pmid":"27863423","id":"PMC_27863423","title":"Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27863423","citation_count":32,"is_preprint":false},{"pmid":"21942811","id":"PMC_21942811","title":"Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples.","date":"2011","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21942811","citation_count":32,"is_preprint":false},{"pmid":"39535362","id":"PMC_39535362","title":"Integrin β8 Facilitates Macrophage Infiltration and Polarization by Regulating CCL5 to Promote LUAD Progression.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39535362","citation_count":31,"is_preprint":false},{"pmid":"33723230","id":"PMC_33723230","title":"Neddylation pathway alleviates chronic pancreatitis by reducing HIF1α-CCL5-dependent macrophage infiltration.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33723230","citation_count":31,"is_preprint":false},{"pmid":"16547971","id":"PMC_16547971","title":"CCL5 evokes calcium signals in microglia through a kinase-, phosphoinositide-, and nucleotide-dependent mechanism.","date":"2006","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/16547971","citation_count":30,"is_preprint":false},{"pmid":"15589034","id":"PMC_15589034","title":"The expression of RANTES and chemokine receptors in the brains of scrapie-infected mice.","date":"2005","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/15589034","citation_count":30,"is_preprint":false},{"pmid":"25280942","id":"PMC_25280942","title":"IL-32θ downregulates CCL5 expression through its interaction with PKCδ and STAT3.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25280942","citation_count":29,"is_preprint":false},{"pmid":"34877932","id":"PMC_34877932","title":"TTP protects against acute liver failure by regulating CCL2 and CCL5 through m6A RNA methylation.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34877932","citation_count":29,"is_preprint":false},{"pmid":"32973762","id":"PMC_32973762","title":"Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma Regression.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32973762","citation_count":28,"is_preprint":false},{"pmid":"17721998","id":"PMC_17721998","title":"Expression of RANTES and MCP-1 in epithelial cells is regulated via LMP1 and CD40.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17721998","citation_count":28,"is_preprint":false},{"pmid":"15377675","id":"PMC_15377675","title":"Recombinant guinea pig CCL5 (RANTES) differentially modulates cytokine production in alveolar and peritoneal macrophages.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15377675","citation_count":28,"is_preprint":false},{"pmid":"33664576","id":"PMC_33664576","title":"Research Trends and Regulation of CCL5 in Prostate Cancer.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33664576","citation_count":26,"is_preprint":false},{"pmid":"37769321","id":"PMC_37769321","title":"The intricate role of CCL5/CCR5 axis in Alzheimer disease.","date":"2023","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37769321","citation_count":26,"is_preprint":false},{"pmid":"33781821","id":"PMC_33781821","title":"Role of myeloid-derived chemokine CCL5/RANTES at an early stage of atherosclerosis.","date":"2021","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33781821","citation_count":26,"is_preprint":false},{"pmid":"18700040","id":"PMC_18700040","title":"CCL5 regulation of mucosal chlamydial immunity and infection.","date":"2008","source":"BMC microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18700040","citation_count":25,"is_preprint":false},{"pmid":"25791723","id":"PMC_25791723","title":"Oligomerized, filamentous surface presentation of RANTES/CCL5 on vascular endothelial cells.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25791723","citation_count":25,"is_preprint":false},{"pmid":"21707929","id":"PMC_21707929","title":"CCL5 (RANTES) gene polymorphisms in pulmonary tuberculosis patients of south India.","date":"2011","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/21707929","citation_count":24,"is_preprint":false},{"pmid":"34490131","id":"PMC_34490131","title":"The Chemokine CCL5 Inhibits the Replication of Influenza A Virus Through SAMHD1 Modulation.","date":"2021","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34490131","citation_count":24,"is_preprint":false},{"pmid":"15609310","id":"PMC_15609310","title":"Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15609310","citation_count":23,"is_preprint":false},{"pmid":"22292067","id":"PMC_22292067","title":"Regulation of CCL5 expression in smooth muscle cells following arterial injury.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22292067","citation_count":23,"is_preprint":false},{"pmid":"14579276","id":"PMC_14579276","title":"Intrapulmonary targeting of RANTES/CCL5-responsive cells prevents chronic fungal asthma.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14579276","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52231,"output_tokens":9114,"usd":0.146702,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19162,"output_tokens":6884,"usd":0.133955,"stage2_stop_reason":"end_turn"},"total_usd":0.280657,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal and solution structures of CCL5 reveal that oligomerization is a polymerization process forming rod-shaped, double-helical oligomers. The CCL5 oligomer uses a positively charged KKWVR motif for glycosaminoglycan (GAG) binding, which is distinct from the partially buried BBXB motif used by monomers/dimers. Oligomerization and GAG binding are structurally separable features of CCL5 function.\",\n      \"method\": \"X-ray crystallography, biophysical analyses, mutational analysis of GAG-binding and oligomerization mutants\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures of CCL5 and GAG-bound oligomers with mutational validation in a single rigorous study\",\n      \"pmids\": [\"27091995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NMR structural analysis of CCL5 dimers bound to chondroitin sulfate oligosaccharides shows that, in addition to the BBXB motif in the 40s loop, GAGs also contact residues in the N loop. GAG binding orientation is highly dependent on the sulfation pattern of N-acetylgalactosamine groups.\",\n      \"method\": \"Solution NMR, paramagnetic relaxation enhancement, intermolecular NOE constraints, structural modeling\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR with multiple orthogonal constraints (PRE, NOE) in a single rigorous structural study\",\n      \"pmids\": [\"25982530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL5 binds to the surface of human endothelial cells in a regular filamentous pattern dependent on heparan sulfate. CCL5 mutants restricted in heparin binding, dimerization, or tetramerization failed to form filaments, suggesting that higher-order oligomers and GAG binding are required for physiologically relevant surface presentation and leukocyte recruitment.\",\n      \"method\": \"Immunofluorescence, electron microscopy, flow chamber assay, heparan sulfate-deficient cell lines, CCL5 oligomerization/GAG-binding mutants\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (EM, IF, functional flow assay) with structure-function mutants in a single study\",\n      \"pmids\": [\"25791723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RANTES/CCL5 secreted by thrombin-stimulated platelets is immobilized on inflamed or atherosclerotic endothelial surfaces and triggers shear-resistant monocyte arrest under flow conditions. This deposition requires endothelial activation (e.g., by IL-1β) and is blocked by the RANTES receptor antagonist Met-RANTES or anti-RANTES antibody.\",\n      \"method\": \"ELISA, immunofluorescence, parallel-wall flow chamber with video microscopy, Met-RANTES/antibody inhibition, immunohistochemistry in ApoE-/- mice, ex vivo carotid artery perfusion\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, replicated across human and murine systems\",\n      \"pmids\": [\"11282909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RANTES/CCL5 activates a G protein-coupled receptor (GPCR)-independent signaling pathway through interaction with glycosaminoglycan (GAG) chains of CD44. This RANTES–CD44 association forms a signaling complex containing CD44, Src kinases, and adapter molecules, activating the p44/42 MAPK pathway. CD44 knockdown via RNA interference abolished p44/42 MAPK activation by RANTES and reduced HIV-1 infectivity enhancement.\",\n      \"method\": \"Co-immunoprecipitation, RNA interference (CD44 knockdown), p44/42 MAPK phosphorylation assays, HeLa-CD4 cell HIV infectivity assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, RNAi knockdown, and functional HIV assay; multiple orthogonal methods in one study\",\n      \"pmids\": [\"12714503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCR5-mediated signaling by RANTES induces early responses (Ca2+ influx, receptor dimerization, tyrosine phosphorylation, Gαi and JAK/STAT association). In contrast to native RANTES, the derivative (AOP)-RANTES fails to trigger late responses including FAK association with the receptor complex, cell polarization, and chemotaxis, demonstrating that late signaling events are separable from early ones and are required for migration.\",\n      \"method\": \"CCR5-transfected HEK-293 cells, Ca2+ flux assays, receptor dimerization assays, tyrosine phosphorylation assays, FAK co-immunoprecipitation, chemotaxis assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays with pharmacological dissection of early vs. late signaling in a single study\",\n      \"pmids\": [\"10037796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL5-induced apoptosis in CCR5-expressing T cells requires (1) CCR5 expression, (2) tyrosine 339 of CCR5, (3) cell surface GAG binding (heparin/chondroitin sulfate addition or GAG digestion protects from death), and (4) higher-order CCL5 oligomerization—the non-GAG-binding mutant (44AANA47)-CCL5 and the dimer-restricted E66S mutant fail to induce apoptosis, while tetramer-forming E26A does. Apoptosis involves cytochrome c release, caspase-9 and caspase-3 activation, and PARP cleavage.\",\n      \"method\": \"CCR5-expressing and CCR5-null T cell lines, CCR5 tyrosine mutant (Y339F), GAG-binding CCL5 mutants, oligomerization CCL5 mutants, caspase activity assays, cytochrome c release assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution with structure-function mutants (receptor and ligand), multiple mechanistic readouts in one study\",\n      \"pmids\": [\"16807236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL5 promotes migration of human osteosarcoma cells through CCR5 (not CCR1 or CCR3) by activating MEK→ERK→NF-κB signaling, which upregulates αvβ3 integrin expression. CCR5 siRNA/antibody/inhibitor and CCL5 shRNA each reduce migration and integrin upregulation.\",\n      \"method\": \"siRNA knockdown, CCR5 antibody, pharmacological inhibitors (MEK, ERK, NF-κB), integrin expression assays, migration assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors with siRNA validation in a single study, single lab\",\n      \"pmids\": [\"22506069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL5-induced migration and invasion of human hepatoma cells through CCR1 requires syndecan-1 (SDC-1) and syndecan-4 (SDC-4) as co-receptors. Antibody blockade or siRNA knockdown of SDC-1 or SDC-4 reduces CCL5-induced chemotaxis and spreading. A GAG-binding-deficient CCL5 mutant (R47K) has no effect, confirming the necessity of chemokine–proteoglycan interaction. Oligomerization interference also reduces CCL5-mediated chemotaxis.\",\n      \"method\": \"Pharmacological inhibitors (FAK, PI3K, MAPK, ROCK), RNA interference (SDC-1, SDC-4), CCL5 oligomerization and GAG-binding mutants, Boyden chamber migration/invasion assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi + mutant CCL5 + pharmacological inhibitors with migration assay, single lab\",\n      \"pmids\": [\"19632304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL5 promotes oral cancer cell migration by inducing MMP-9 expression through CCR5 via activation of PLC→PKCδ→NF-κB signaling. MMP-9 siRNA abrogates CCL5-induced migration, placing MMP-9 downstream of CCL5/CCR5 in this pathway.\",\n      \"method\": \"RT-PCR, flow cytometry, siRNA (MMP-9), specific pharmacological inhibitors (PLC, PKCδ, NF-κB), migration and invasion assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown combined with pharmacological pathway dissection, single lab\",\n      \"pmids\": [\"19334035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RANTES/CCL5 induces MMP-1 and MMP-13 expression in rheumatoid arthritis synovial fibroblasts (RASFs) through PKCδ, JNK, and ERK signaling, leading to collagenase activity and collagen triple-helix degradation. Heparan sulfate proteoglycan (HSPG) digestion by heparinase III or Met-RANTES pre-treatment completely abrogates MMP induction. CCL5 siRNA also reduces IL-1β-induced MMP expression, placing CCL5 upstream of IL-1β-driven MMP production.\",\n      \"method\": \"3D micromass culture, collagenase activity assay, circular dichroism spectroscopy, siRNA, Met-RANTES antagonist, heparinase III, specific kinase inhibitors\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (siRNA, enzyme digestion, inhibitors, structural assay), single lab\",\n      \"pmids\": [\"29093715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Rantes/CCL5 influences hematopoietic stem cell (HSC) subtype distribution and causes myeloid skewing. Forced CCL5 overexpression reduced T-cell output; brief ex vivo CCL5 exposure decreased T-cell progeny and increased myeloid progenitors. CCL5 knockout mice show decreased myeloid-biased HSCs and myeloid progenitors, increased lymphoid-biased HSCs, and decreased mTOR activity in KLS cells.\",\n      \"method\": \"Retroviral overexpression, knockout mice, transplantation assays, flow cytometry, mTOR activity measurement\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with defined cellular phenotypes, single lab\",\n      \"pmids\": [\"22289892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL5 released by activated platelets (via TRAP stimulation) increases megakaryocyte (MK) proplatelet formation and ploidy through CCR5. Maraviroc (CCR5 antagonist) or CCL5 immunodepletion of platelet releasate abolished most of this effect. Mechanistically, CCL5/CCR5 may increase MK ploidy and proplatelet formation by suppressing apoptosis through the Akt signaling pathway.\",\n      \"method\": \"MK culture with platelet releasate, recombinant CCL5, maraviroc, CCL5 immunodepletion, ploidy measurements, Akt signaling assays, in vivo murine colitis model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and immunodepletion approaches with in vitro and in vivo confirmation, single lab\",\n      \"pmids\": [\"26647394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The Fli-1 transcription factor (Ets family) directly binds Ets binding sites in the distal CCL5 promoter and drives CCL5 transcription in a dose-dependent manner. Fli-1 knockdown (siRNA) in endothelial cells significantly decreased CCL5 protein. Ets1 acts as a dominant-negative for Fli-1 at shared binding sites. A 225-bp region of the CCL5 promoter contains the critical Fli-1 binding sites.\",\n      \"method\": \"ChIP, siRNA knockdown, transient transfection with promoter-reporter constructs, promoter deletion and mutation analysis\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, siRNA, and reporter assays, single lab\",\n      \"pmids\": [\"25098295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"YB-1 phosphorylated at Ser-102 (mediated through Akt signaling) binds the CCL5 promoter with greater affinity and trans-activates CCL5 expression during monocyte differentiation. Calcineurin (CN) dephosphorylates YB-1 at Ser-102, preventing its binding to the CCL5 promoter and thereby downregulating CCL5. Co-immunoprecipitation confirmed a direct YB-1/CN interaction.\",\n      \"method\": \"Co-immunoprecipitation, promoter-reporter assays, Akt pathway inhibitors, calcineurin inhibitor (cyclosporine A), ChIP, in vivo mouse kidney tissue analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, promoter assay, and in vivo validation, single lab\",\n      \"pmids\": [\"24947514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Activation of Nod1 and Nod2 (intracellular pattern recognition receptors) induces CCL5 secretion in murine macrophages via the NF-κB pathway (not via interferon-β signaling). In vivo, intraperitoneal injection of Nod1 or Nod2 agonists rapidly elevates CCL5 in blood. NF-κB was identified as the key signaling pathway by promoter stimulation assays.\",\n      \"method\": \"Macrophage stimulation assays, in vivo agonist injection, promoter-reporter assays, NF-κB pathway analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo experiments with promoter validation, single lab\",\n      \"pmids\": [\"17705131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASIC1a (acid-sensing ion channel 1a) mediates Ca2+ influx in rheumatoid arthritis synovial fibroblasts, which activates NFATc3 nuclear translocation. NFATc3 then directly binds the RANTES/CCL5 promoter and activates CCL5 transcription, as shown by ChIP-qPCR and dual-luciferase reporter assay.\",\n      \"method\": \"Calcium imaging, flow cytometry, ChIP-qPCR, dual-luciferase reporter assay, Western blot, immunofluorescence, adjuvant-induced arthritis rat model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays establishing direct promoter binding, supported by in vivo model, single lab\",\n      \"pmids\": [\"31903118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"EBV latent membrane protein 1 (LMP-1) transactivates CCL5 expression via both CTAR-1 and CTAR-2 domains through NF-κB signaling. Dominant-negative constructs for IκBα, IκBβ, IKKα, IKKβ, NIK, and TRAF2 inhibited LMP-1-driven CCL5 promoter activation. The NF-κB binding sites (R(A/B)) at positions -71 to -43 of the CCL5 promoter are essential.\",\n      \"method\": \"CCL5 promoter-reporter assays, dominant-negative NF-κB pathway constructs, RT-PCR, ELISA in EBV-infected and EBV-negative cell lines\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mapping with dominant-negative constructs, single lab\",\n      \"pmids\": [\"15609310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL5 expression in vascular smooth muscle cells (SMCs) following arterial injury is mediated by IRF-1 binding to an IRF-1 response element in the CCL5 promoter. p38 MAPK suppresses CCL5 expression through MKK3, and the downstream molecule MK2 selectively mediates p38-dependent CCL5 (but not IP-10) inhibition in SMCs.\",\n      \"method\": \"Balloon artery injury model in rats, SMC culture, promoter-reporter assays, qRT-PCR, pharmacological inhibitors (p38 MAPK, MKK3), MK2 knockdown\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter assay identifying IRF-1 site combined with kinase pathway analysis in vitro and in vivo, single lab\",\n      \"pmids\": [\"22292067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-1 induces RANTES/CCL5 expression in human astrocytes through NF-κB, p38 MAPK, and JNK pathways (but not ERK). IFNβ synergizes with IL-1 by enhancing p38 phosphorylation and by co-inducing nuclear C/EBPβ and ISRE complexes containing Stat1, Stat2, and IRF-1. Mutated promoter-reporter constructs implicated κB, ISRE, and C/EBPβ sites as necessary for IL-1/IFNβ-induced CCL5 transcription.\",\n      \"method\": \"RNase protection assay, ELISA, promoter-reporter constructs with site mutations, pharmacological inhibitors (p38, JNK, ERK), super-repressor IκBα transfection, EMSA for nuclear complexes\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mapping with multiple mutants and pathway inhibitors, single lab\",\n      \"pmids\": [\"15228586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HIV-1 Vpr and Nef are required for RANTES/CCL5 induction in primary human microglia. Inhibition of reverse transcription (AZT) blocked CCL5 induction, indicating that productive viral replication is necessary. p38 MAPK plays a negative regulatory role (its specific inhibitor SB203580 augmented CCL5 expression).\",\n      \"method\": \"HIV infection of primary microglia with accessory gene mutants, AZT reverse transcriptase inhibitor, p38 MAPK inhibitor (SB203580), RT-PCR and protein assays\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — viral mutant panel with pharmacological dissection, single lab\",\n      \"pmids\": [\"12359436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL5/CCR5 signaling in microglia activates intracellular Ca2+ elevation through a multi-step pathway requiring JAK activity, inhibitory G protein, PI3K, Bruton's tyrosine kinase, PLC-mediated IP3-sensitive Ca2+ store release, and NAD metabolites (cADPR for intracellular Ca2+ release; ADPR for Ca2+ influx via a nimodipine-sensitive channel).\",\n      \"method\": \"Fura-2 digital imaging of [Ca2+]i, pharmacological inhibitors targeting each step (JAK, Gi, PI3K, Btk, PLC), cADPR and ADPR application, nimodipine block\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic pharmacological dissection with multiple inhibitors targeting distinct pathway steps, single lab\",\n      \"pmids\": [\"16547971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL5 secreted by pericytes activates CCR5 on GBM cells to enable DNA-PKcs-mediated DNA damage repair (DDR) upon temozolomide treatment. Disrupting CCL5-CCR5 paracrine signaling with maraviroc inhibits pericyte-promoted DDR and enhances TMZ cytotoxicity in GBM xenografts.\",\n      \"method\": \"Genetic pericyte depletion in xenografts, CCR5 antagonist (maraviroc), DNA-PKcs activity assays, GBM patient-derived xenografts, in vivo survival experiments\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic depletion plus pharmacological inhibition with mechanistic DDR readout in vivo, single lab\",\n      \"pmids\": [\"34239070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL5/CCR5 promotes angiogenic effects that depend on VEGF secretion by endothelial cells, CCR1 and CCR5 receptor signaling, and GAG (heparan sulfate proteoglycan) binding via SDC-1, SDC-4, and CD44. CCL5 mutants impaired in oligomerization ([E66A]) or GAG binding ([44AANA47]) fail to induce angiogenic effects in vitro and in vivo, establishing that both oligomerization and GAG binding are required for RANTES/CCL5-induced angiogenesis.\",\n      \"method\": \"In vitro endothelial migration/spreading/tube formation assays, in vivo rat subcutaneous neovascularization model, anti-VEGF receptor antibodies, CCL5 mutants ([E66A], [44AANA47]), siRNA for SDC-1/SDC-4, MMP-9 activity assays\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo with CCL5 mutants and siRNA, single lab\",\n      \"pmids\": [\"22752444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IL-32θ downregulates CCL5 expression by interacting with PKCδ and STAT3. This interaction leads to STAT3 phosphorylation at Ser727, rendering STAT3 transcriptionally inactive at the CCL5 promoter. Co-IP and pulldown assays confirmed direct IL-32θ/PKCδ and IL-32θ/STAT3 interactions.\",\n      \"method\": \"Co-immunoprecipitation, pulldown assay, ELISA, STAT3 Ser727 phosphorylation assay, ChIP for STAT3 at CCL5 promoter\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and pulldown establishing protein interactions with ChIP for promoter occupancy, single lab\",\n      \"pmids\": [\"25280942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Tristetraprolin (TTP) promotes N6-methyladenosine (m6A) methylation on CCL5 mRNA, destabilizing it and reducing CCL5 levels. TTP overexpression upregulates m6A methylation enzymes (WTAP, METTL14, YTHDF2), globally increasing m6A and specifically decreasing CCL5 mRNA stability, ameliorating acute liver failure in vivo.\",\n      \"method\": \"m6A sequencing, RNA stability assays, TTP overexpression in vivo, methyltransferase expression analysis, in vivo murine acute liver failure model\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with m6A mechanistic readout in vitro and in vivo, single lab\",\n      \"pmids\": [\"34877932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL5/RANTES contributes to hypothalamic insulin signaling through CCR5, which co-localizes and co-immunoprecipitates with insulin receptors in the arcuate nucleus. CCL5/CCR5 activates the PI3K-Akt pathway and reduces inhibitory phosphorylation of IRS-1 at Ser302 via AMPKα-S6 kinase signaling, promoting GLUT4 membrane translocation. Intracerebroventricular Met-CCL5 blocks hypothalamic insulin signaling and induces peripheral glucose intolerance.\",\n      \"method\": \"Co-immunoprecipitation, immunostaining, ex vivo and in vitro stimulation assays, CCR5/CCL5 knockout mice, GLUT4 translocation assay, intracerebroventricular drug delivery\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, knockout mice with defined metabolic phenotypes, and pharmacological validation, single lab\",\n      \"pmids\": [\"27898058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL5 supports hippocampal synaptic function and memory formation by promoting bioenergy metabolism: fructose/mannose degradation, glycolysis, gluconeogenesis, glutamate and purine metabolism, ATP generation, and mitochondrial structural integrity. Re-expressing CCL5 in CCL5-knockout mouse hippocampus restored synaptic protein expression, neuronal connectivity, and cognitive function.\",\n      \"method\": \"CCL5 knockout mice, hippocampal LTP measurement, metabolomics, FDG-PET imaging, Seahorse metabolic analysis, AAV re-expression, behavioral assays\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal metabolic and functional readouts with rescue experiment, single lab\",\n      \"pmids\": [\"33931731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RANTES expression in T lymphocytes requires the Krüppel-like transcription factor RFLAT-1 (KLF13), which is itself expressed late after T-cell activation. Uniquely, RFLAT-1 expression is translationally rather than transcriptionally regulated, explaining the 3–5 day delayed kinetics of RANTES expression in activated T cells.\",\n      \"method\": \"Promoter characterization, transcription factor identification and characterization, T-cell activation time-course experiments\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — identification and characterization of a novel regulator with defined promoter function, single lab\",\n      \"pmids\": [\"11138780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The RANTES gene spans ~7.1 kb with three exons and two introns, and has a 1-kb promoter containing consensus elements for T cell/hematopoietic, myeloid, muscle, and ubiquitous transcription factors. Promoter-luciferase assays and deletion analysis show that different transcriptional mechanisms regulate RANTES expression in different cell types (e.g., high in mature T cells Hut78 but not in early T cell lines), and that the kinetics of RANTES mRNA expression differ between cell types (late in T cells, early in fibroblasts/epithelial cells after TNF-α).\",\n      \"method\": \"Gene sequencing, promoter-luciferase reporter assays, deletion analysis, Northern blot\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter-reporter assays with deletion analysis in multiple cell types, single lab\",\n      \"pmids\": [\"7689610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL5 inhibits influenza A virus (IAV) replication in alveolar epithelial cells by upregulating the restriction factor SAMHD1. CCL5-mediated SAMHD1 upregulation is dependent on PKC signaling. SAMHD1 knockdown abolishes both CCL5-mediated IAV inhibition and CCL5-mediated cell death inhibition.\",\n      \"method\": \"A549 cell CCR5 stimulation with CCL5, RT-PCR restriction factor panel, siRNA knockdown of SAMHD1, PKC inhibition, viral titer assays\",\n      \"journal\": \"Frontiers in cellular and infection microbiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, CCL5-treated cells with siRNA knockdown but indirect mechanism (SAMHD1 as mediator not directly shown for endogenous CCL5 signaling)\",\n      \"pmids\": [\"34490131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RANTES induces a biphasic Ca2+ signal in T cells: an early G protein-mediated phase associated with chemotaxis, and a late tyrosine kinase-linked phase unique to RANTES. The late phase correlates with CD3 expression on Jurkat T cells, and prior TCR stimulation with anti-CD3 suppresses the RANTES-induced second phase, suggesting TCR involvement.\",\n      \"method\": \"Ca2+ flux measurements, Jurkat cell sorting by CD3 expression, anti-CD3 mAb stimulation, comparison of CD3-high vs. CD3-low populations\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, correlation between CD3 expression and RANTES response with limited mechanistic follow-up\",\n      \"pmids\": [\"9552000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL5 promotes macrophage survival in adipose tissue by protecting macrophages from free cholesterol-induced apoptosis via activation of Akt and ERK pathways. CCL5 also triggers adhesion and transmigration of blood monocytes through adipose tissue endothelial cells.\",\n      \"method\": \"Macrophage apoptosis assays (free cholesterol model), Akt/ERK pathway activation assays, monocyte transmigration assay through adipose tissue endothelial cells\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional cellular assays without deep pathway dissection or genetic validation, single lab\",\n      \"pmids\": [\"19893003\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL5 (RANTES) is a secreted CC-chemokine that acts primarily through G protein-coupled receptors CCR1, CCR3, and CCR5, but also through a GPCR-independent pathway via CD44–glycosaminoglycan (GAG) interaction that activates Src kinases and p44/42 MAPK; CCL5 undergoes higher-order oligomerization (forming double-helical rod-shaped polymers) that, together with GAG/heparan sulfate proteoglycan binding via a KKWVR motif, is essential for immobilization on endothelial surfaces, leukocyte arrest under flow, induction of apoptosis in T cells, and pro-angiogenic activity; its transcription is regulated by NF-κB (downstream of Nod1/2, LMP-1, IL-1, TNF-α), IRF-1, Fli-1/Ets family factors, KLF13/RFLAT-1 (translationally controlled in T cells), NFATc3 (downstream of Ca2+ influx via ASIC1a), and YB-1 (controlled by Akt-mediated phosphorylation and calcineurin-mediated dephosphorylation); CCL5 mRNA stability is regulated by TTP-mediated m6A methylation; and downstream of CCR5, CCL5 drives cell migration via MEK/ERK/NF-κB/integrin, PKCδ/JNK/ERK/MMP, and PI3K/Akt/GLUT4 pathways in different cell types, while also supporting hypothalamic insulin signaling, hippocampal synaptic bioenergetics, and pericyte-driven DNA-PKcs-mediated chemoresistance in glioblastoma.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCL5 (RANTES) is a secreted CC-chemokine that orchestrates leukocyte recruitment, inflammation, and tissue remodeling through receptor engagement coupled to glycosaminoglycan (GAG)-dependent surface presentation [#0, #3]. Structurally, CCL5 polymerizes into rod-shaped, double-helical higher-order oligomers, and oligomerization is functionally separable from GAG binding: oligomers engage GAGs through a positively charged KKWVR motif distinct from the BBXB motif used by monomers/dimers, while NMR shows dimer-GAG contacts also extend to the N loop in a sulfation-dependent manner [#0, #1]. This higher-order assembly is required for the regular, heparan sulfate-dependent filamentous deposition of CCL5 on endothelial surfaces that enables shear-resistant monocyte arrest under flow, with platelet-derived CCL5 immobilized on activated and atherosclerotic endothelium [#2, #3]. The same oligomerization- and GAG-dependent logic governs CCL5-induced T-cell apoptosis (requiring CCR5, its Tyr339, and surface GAGs, with caspase-9/-3 activation and cytochrome c release) and pro-angiogenic activity dependent on syndecan-1/-4 and CD44 and on VEGF secretion [#6, #23]. CCL5 signals canonically through CCR5 (and CCR1/CCR3), where early Ca2+ and JAK/STAT responses are separable from late FAK-dependent polarization and chemotaxis [#5], and additionally through a GPCR-independent route via CD44-GAG that assembles a CD44/Src complex activating p44/42 MAPK [#4]. Downstream of CCR5/CCR1, CCL5 drives migration, invasion, and matrix remodeling across cell types via MEK/ERK/NF-\\u03baB-driven \\u03b1v\\u03b23 integrin induction, PLC/PKC\\u03b4/NF-\\u03baB-driven MMP-9, and PKC\\u03b4/JNK/ERK-driven MMP-1/MMP-13 collagenase activity [#7, #9, #10]. Beyond inflammation, CCL5/CCR5 supports hematopoietic stem cell myeloid skewing, megakaryocyte proplatelet formation, hypothalamic insulin signaling and GLUT4 translocation, hippocampal synaptic bioenergetics, and pericyte-driven DNA-PKcs-mediated chemoresistance in glioblastoma [#11, #12, #26, #27, #22]. CCL5 transcription is controlled in a cell-type- and stimulus-specific manner by NF-\\u03baB (downstream of Nod1/2, EBV LMP-1, and IL-1), IRF-1, the Ets factor Fli-1, KLF13/RFLAT-1 (translationally regulated in T cells), NFATc3 (downstream of ASIC1a-mediated Ca2+ influx), and Akt-phosphorylated YB-1, while m6A methylation promoted by tristetraprolin destabilizes CCL5 mRNA [#15, #17, #19, #18, #13, #28, #16, #14, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing the RANTES gene structure and promoter defined that its expression is cell-type-specific and kinetically distinct, framing the question of which factors drive transcription in each context.\",\n      \"evidence\": \"Gene sequencing, promoter-luciferase deletion analysis, and Northern blot across T-cell, fibroblast, and epithelial lines\",\n      \"pmids\": [\"7689610\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Individual transcription factors binding the mapped elements were not identified\", \"Kinetic differences between cell types were described but not mechanistically explained\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Resolving how CCL5 signals in T cells showed a biphasic Ca2+ response, separating a chemotactic G protein phase from a late tyrosine kinase phase linked to TCR/CD3.\",\n      \"evidence\": \"Ca2+ flux in CD3-sorted Jurkat cells with anti-CD3 stimulation\",\n      \"pmids\": [\"9552000\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Correlation between CD3 expression and the late phase, not a defined mechanism\", \"Molecular link between TCR and CCL5 signaling not established\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identifying RFLAT-1/KLF13 as a translationally regulated activator explained the delayed kinetics of RANTES expression in activated T cells.\",\n      \"evidence\": \"Promoter characterization and T-cell activation time-course\",\n      \"pmids\": [\"11138780\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of translational control of KLF13 not detailed\", \"Cooperation with other promoter factors unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that platelet-derived RANTES is immobilized on activated endothelium and triggers shear-resistant monocyte arrest connected CCL5 deposition to atherogenic leukocyte recruitment in vivo.\",\n      \"evidence\": \"Flow chamber video microscopy, Met-RANTES inhibition, ApoE-/- immunohistochemistry, ex vivo carotid perfusion\",\n      \"pmids\": [\"11282909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of endothelial immobilization (GAG/oligomer requirement) not yet defined here\", \"Receptor mediating arrest not specified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapping HIV-1 induction of CCL5 in microglia showed productive replication and Vpr/Nef are required, with p38 acting as a negative regulator.\",\n      \"evidence\": \"HIV accessory gene mutants, AZT, and p38 inhibitor in primary microglia\",\n      \"pmids\": [\"12359436\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcription factor link not established\", \"Generalizability beyond microglia unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery of a GPCR-independent CCL5 pathway through CD44-GAG that assembles a CD44/Src complex activating p44/42 MAPK established a receptor-independent signaling axis.\",\n      \"evidence\": \"Reciprocal Co-IP, CD44 RNAi, MAPK phosphorylation, and HIV infectivity assays\",\n      \"pmids\": [\"12714503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream consequences of CD44/Src signaling beyond MAPK and HIV enhancement not mapped\", \"Physiological contexts using this pathway not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Pharmacological dissection of CCR5 signaling separated early responses (Ca2+, dimerization, JAK/STAT) from late FAK-dependent polarization and chemotaxis, showing late events are required for migration.\",\n      \"evidence\": \"CCR5-transfected HEK-293 cells with (AOP)-RANTES and FAK Co-IP and chemotaxis assays\",\n      \"pmids\": [\"10037796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger distinguishing early vs late signaling not identified\", \"Endogenous receptor context not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defining IL-1/IFN\\u03b2 induction of CCL5 in astrocytes through NF-\\u03baB, p38, JNK, and synergistic ISRE/C/EBP\\u03b2 complexes identified the cytokine-driven transcriptional circuitry.\",\n      \"evidence\": \"Promoter-reporter mutants, pathway inhibitors, super-repressor I\\u03baB\\u03b1, and EMSA\",\n      \"pmids\": [\"15228586\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each element in vivo not assessed\", \"Cell-type specificity beyond astrocytes unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showing EBV LMP-1 transactivates CCL5 via CTAR domains and NF-\\u03baB through defined promoter sites linked viral oncoprotein signaling to CCL5 induction.\",\n      \"evidence\": \"Promoter-reporter assays with dominant-negative NF-\\u03baB pathway constructs\",\n      \"pmids\": [\"15609310\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance in EBV-associated disease not established\", \"Interplay with other LMP-1-induced genes not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing that CCL5-induced T-cell apoptosis requires CCR5 Tyr339, surface GAGs, and higher-order oligomerization tied the chemokine's structural assembly directly to a death-inducing function.\",\n      \"evidence\": \"CCR5 and ligand structure-function mutants with caspase and cytochrome c readouts\",\n      \"pmids\": [\"16807236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling steps linking oligomerized CCL5 to mitochondrial apoptosis not fully mapped\", \"Physiological setting of T-cell killing not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Dissecting CCL5/CCR5-evoked Ca2+ signaling in microglia revealed a multi-step JAK/Gi/PI3K/Btk/PLC cascade using cADPR and ADPR as second messengers.\",\n      \"evidence\": \"Fura-2 imaging with systematic pharmacological inhibition and nucleotide application\",\n      \"pmids\": [\"16547971\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular targets of cADPR/ADPR not identified\", \"Functional output of the Ca2+ signal not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Characterizing CCL5-driven migration in multiple cancer types established proteoglycan co-receptors (syndecan-1/-4) and PKC\\u03b4/NF-\\u03baB-driven MMP-9 as effectors of invasion.\",\n      \"evidence\": \"RNAi of SDC-1/SDC-4 and MMP-9, GAG-binding-deficient CCL5 mutants, and pathway inhibitors in hepatoma and oral cancer cells\",\n      \"pmids\": [\"19632304\", \"19334035\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these pathways operate in primary tumors not shown\", \"Receptor selectivity (CCR1 vs CCR5) context-dependent\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linking CCL5 to macrophage survival and monocyte transmigration in adipose tissue extended its role to metabolic-tissue inflammation.\",\n      \"evidence\": \"Macrophage apoptosis and transmigration assays with Akt/ERK readouts\",\n      \"pmids\": [\"19893003\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No genetic validation or deep pathway dissection\", \"Receptor mediating the effect not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Multiple gain/loss-of-function studies defined CCL5 transcriptional regulators and a hematopoietic role, including IRF-1-driven expression in injured vessels and CCL5-dependent myeloid skewing of HSCs.\",\n      \"evidence\": \"IRF-1 promoter mapping with p38/MKK3/MK2 dissection in injured arteries; CCL5 overexpression and knockout mice in HSC transplantation\",\n      \"pmids\": [\"22292067\", \"22289892\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor for the HSC effect not identified\", \"Connection between transcriptional control and hematopoietic phenotype not integrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showing CCL5/CCR5 induces \\u03b1v\\u03b23 integrin via MEK/ERK/NF-\\u03baB and contributes GAG- and oligomerization-dependent angiogenesis tied receptor signaling and structural assembly to tumor-relevant cell behaviors.\",\n      \"evidence\": \"siRNA/inhibitor migration assays in osteosarcoma; CCL5 mutants, SDC siRNA, anti-VEGFR antibodies in angiogenesis models\",\n      \"pmids\": [\"22506069\", \"22752444\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Integration of GPCR and GAG inputs during angiogenesis unresolved\", \"In vivo tumor angiogenesis relevance limited to single models\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying Fli-1, Akt-phosphorylated YB-1 (countered by calcineurin), and IL-32\\u03b8/PKC\\u03b4/STAT3 as regulators expanded the CCL5 transcriptional network and its post-translational control.\",\n      \"evidence\": \"ChIP, siRNA, promoter-reporter, and Co-IP across endothelial, monocyte, and other systems\",\n      \"pmids\": [\"25098295\", \"24947514\", \"25280942\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hierarchy among these factors not established\", \"Combinatorial control in a single cell type not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"High-resolution structural work defined how CCL5 dimers and oligomers contact GAGs and established that filamentous endothelial deposition requires both higher-order oligomerization and heparan sulfate binding.\",\n      \"evidence\": \"Solution NMR with PRE/NOE constraints; EM/IF/flow chamber with oligomerization and GAG-binding mutants\",\n      \"pmids\": [\"25982530\", \"25791723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of polymer assembly on living endothelium not directly observed\", \"Link from filament geometry to specific receptor engagement not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that platelet-released CCL5 increases megakaryocyte proplatelet formation and ploidy through CCR5/Akt extended CCL5 function to thrombopoiesis.\",\n      \"evidence\": \"MK culture with releasate, maraviroc, CCL5 immunodepletion, and an in vivo colitis model\",\n      \"pmids\": [\"26647394\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CCR5 signaling steps to ploidy not fully mapped\", \"Apoptosis-suppression mechanism described as putative\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Crystal/solution structures resolved CCL5 as a polymerizing chemokine forming double-helical oligomers using a KKWVR GAG-binding motif distinct from the monomer/dimer BBXB motif, making oligomerization and GAG binding structurally separable.\",\n      \"evidence\": \"X-ray crystallography and biophysics with GAG-binding and oligomerization mutants\",\n      \"pmids\": [\"27091995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo dependence of each motif on specific functions not exhaustively tested\", \"Polymer length regulation not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying CCL5/CCR5 as a positive regulator of hypothalamic insulin signaling via PI3K-Akt and AMPK\\u03b1-S6K modulation of IRS-1 extended CCL5 into central metabolic control.\",\n      \"evidence\": \"Co-IP of CCR5 with insulin receptor, knockout mice, GLUT4 translocation, and intracerebroventricular Met-CCL5\",\n      \"pmids\": [\"27898058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of CCR5-insulin receptor cross-talk not structurally defined\", \"Relevance to systemic insulin resistance only partly addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Establishing the ASIC1a-Ca2+-NFATc3 axis as a direct CCL5 promoter activator linked ion-channel-driven calcium signaling to CCL5 transcription in arthritis.\",\n      \"evidence\": \"Calcium imaging, ChIP-qPCR, dual-luciferase reporter, and an adjuvant-induced arthritis model\",\n      \"pmids\": [\"31903118\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cooperation of NFATc3 with NF-\\u03baB at the promoter not dissected\", \"Generalizability beyond synovial fibroblasts unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Multiple studies expanded CCL5 into matrix degradation, RNA-level control, neuronal bioenergetics, antiviral restriction, and tumor chemoresistance, broadening its mechanistic reach.\",\n      \"evidence\": \"Collagenase/CD/siRNA in RA fibroblasts (MMP-1/-13); m6A-seq and TTP overexpression; CCL5-KO hippocampal metabolomics and rescue; SAMHD1 knockdown in A549; pericyte depletion and maraviroc in GBM xenografts\",\n      \"pmids\": [\"29093715\", \"34877932\", \"33931731\", \"34490131\", \"34239070\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each role established in a single lab/model\", \"Connections among these diverse functions not integrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CCL5 oligomer geometry, GAG binding, and receptor (CCR1/3/5 vs CD44) engagement are integrated to select among migration, apoptosis, angiogenesis, and metabolic outputs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking structural assembly state to functional output\", \"Quantitative receptor occupancy on GAG-immobilized oligomers in vivo not measured\", \"Cross-talk between GPCR-dependent and CD44-dependent pathways not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [4, 5, 7, 22, 26]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0005102\", \"supporting_discovery_ids\": [0, 2, 8, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 23]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 6, 11, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 7, 21, 26]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [13, 14, 16, 17, 19, 28]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [3, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCR5\", \"CCR1\", \"CD44\", \"SDC1\", \"SDC4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}